Clinical Trials · NCT02365584

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

TerminatedPhase 2Lanreotide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Ipsen
Enrollment
43
Start date
Jan 2015
Locations
13 sites, Italy
Primary endpoint
Least Squares (LS) Mean Area Under Curve (AUC) of Edmonton Symptom Assessment System (ESAS) Total Scores Collected for the First 7 Days; Full Analysis Set (FAS)
View Lanreotide compound reference